Research graph
References from Rethinking anti-BCMA T-cell engager design. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s2352-3026(26)00228-0 · 2026 · Admitted local publication
Teclistamab in relapsed or refractory multiple myeloma
10.1056/nejmoa2203478 · 2022 · External reference
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
10.1038/s41591-023-02528-9 · 2023 · External reference
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
10.1038/s41591-023-02589-w · 2023 · External reference
Linvoseltamab in patients with relapsed/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses
10.1016/j.clml.2025.11.004 · 2026 · External reference
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
10.3389/fimmu.2023.1190379 · 2023 · External reference
Preclinical and nonclinical characterization of HPN217: a tri-specific t cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma
2018 · External reference
Bispecific antibodies: advancing precision oncology
10.1016/j.trecan.2024.07.002 · 2024 · External reference
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
10.1038/s41591-023-02491-5 · 2023 · External reference
